Evidence report

Vilon Peptide: A Dipeptide Without a Validated Protocol

Vilon is a two-amino-acid peptide promoted as an immune and longevity bioregulator. The searchable literature is mostly experimental and review-level material, not the independent, controlled human evidence needed to validate wellness dosing claims.

Reviewed by the PepGuard team · Last reviewed Jul 28, 2026

Synthetic dipeptide (lysine-glutamic acid) · also sold as Lys-Glu, lysyl-glutamic acid

Identity first

Small molecule, large inference gap.

Vilon is a defined dipeptide, also indexed as lysyl-glutamic acid. That is useful for searching the literature, but it does not make the immune, longevity, or "bioregulator" claims clinically established.

The available record is not a modern, independently replicated program with a defined patient population, dose, comparator, and prespecified clinical outcome. Without that, a course schedule is marketing detail, not a medical finding.

10/100
Preclinical and limited literature; no established human treatment dose or FDA-approved useNo FDA-approved Vilon medicine or approved US indication.
Dosage

No established human Vilon dose.

What's citedRange
Established human clinical doseNone

No controlled human dose-ranging study was identified that supports the online Vilon protocols. The absence of a chart here is intentional: a vendor's capsule or injection schedule is not clinical evidence.

This is not a dosing recommendation. A commercial protocol cannot substitute for a controlled human dose-ranging study.
Safety

The safety record is not characterized.

SignalFrequencyContext
Human adverse-event profileunknown / not studiedNo adequate controlled human safety dataset was identified for the marketed wellness uses.
Product purity, sterility, and dose accuracyunknown / not studiedPublished experimental papers do not verify a commercial product's contents.

A named peptide is not an evidence grade.

Check the research before treating a protocol as established.